CRL Charles River Laboratories International, Inc. Common Stock
$290,01
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 5, 2026
52 Haftlık Aralık
$144–$291
99% of range
Analist Derecelendirmesi
BUY
22 analysts
Fiyat Hedefi
$281
P/E (TTM)
-99.7
ROE
-4.4%
Net Kâr Marjı
-3.6%
Charles River Laboratories International, Inc. Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Devamını oku
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
CRL Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$290.00
Piyasa Değeri
$14.27B
P/E (TTM)
-99.7
EPS (TTM)
$-2.91
Gelir (TTM)
$4.02B
Temettü Verimi
—
ROE
-4.4%
D/E Borç/Özsermaye
0.0
52 Haftlık Aralık
$144 – $291
CRL Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$4.02B
2016-12-31
→
2025-12-27
Hisse Başına Kâr
$-2.91
2016-12-31
→
2025-12-27
Serbest Nakit Akışı
$518M
2016-12-31
→
2025-12-27
Marjlar
-3.6%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
CRL
Akran Ortalaması
P/E (TTM)
-99.7
39.9
P/S (TTM) (F/S (TTM))
3.6
5.6
P/B (F/D)
4.5
4.1
EV / EBITDA
32.8
—
Price / FCF (Fiyat / Serbest Nakit Akışı)
27.5
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
CRL
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
0.63%
—
Net Profit Margin (Net Kâr Marjı)
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
CRL
Akran Ortalaması
Debt / Equity (Borç / Öz Sermaye)
0.0
15.3
Current Ratio (Cari Oran)
1.3
1.7
Quick Ratio (Cari Oran)
0.8
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
CRL
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
-0.85%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
0.33%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
6.6%
—
EPS YoY (EPS YB)
-97.8%
—
Net Income YoY (Net Gelir Yıllık Bazda)
-95.3%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
CRL
Akran Ortalaması
CRL Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
22 analist
- Güçlü Al 5 22,7%
- Al 10 45,5%
- Tut 7 31,8%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
14 analist · 2026-08-14
Medyan
$300.00
Ortalama
$281.00
Şimdi
$290.00
Düşük
$145.00
Yüksek
$318.00
Medyan hedef
$300.00
+3,4%
Ortalama hedef
$281.00
-3,1%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.21%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $3.02 | $2.76 | 0.26% |
| 31 Mart 2026 | $2.06 | $1.96 | 0.10% |
| 31 Aralık 2025 | $2.39 | $2.37 | 0.02% |
| 30 Eylül 2025 | $2.43 | $2.36 | 0.07% |
| 30 Haziran 2025 | $3.12 | $2.52 | 0.60% |
| 31 Mart 2025 | $2.34 | $2.10 | 0.24% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| BIO | — | — | — | — | — | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 15
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Bilanço 30
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Nakit Akışı 18
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Verimlilik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Büyüme Oranları 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Gelir Tablosu 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Bilanço 28
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Nakit Akışı 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Kârlılık 5
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Likidite ve Solventlik 4
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Verimlilik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Değerleme (TTM) 13
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Gelir | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Faaliyet Kâr Marjı % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Net Gelir | $-144M | $22M | $475M | $486M | $391M |
| Seyreltilmiş Hisse Başı Kâr | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Bilanço
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cari Oran | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Cari Oran | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Nakit Akışı
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $518M | $502M | $365M | $295M | $532M |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 617 dosya · $7.8B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 82 (-1 önceki Ç'ye göre) | 59 (-23 önceki Ç'ye göre) | 180 (-11 önceki Ç'ye göre) | 201 (+15 önceki Ç'ye göre) | +5.0M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| FMR LLC | $737.350.307 | 3.251.247 | 9,42% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 9,12% | Hisse senetleri |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 6,49% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 6,40% | Hisse senetleri |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 5,40% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $348.883.077 | 1.538.354 | 4,46% | Hisse senetleri |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 3,46% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $259.130.041 | 1.144.937 | 3,31% | Hisse senetleri |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 3,24% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $223.361.616 | 984.883 | 2,85% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $192.886.814 | 850.503 | 2,46% | Hisse senetleri |
| NEUBERGER BERMAN GROUP LLC | $192.182.793 | 847.488 | 2,45% | Hisse senetleri |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 2,26% | Hisse senetleri |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 2,19% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,93% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 1,41% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $104.921.899 | 462.639 | 1,34% | Hisse senetleri |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 1,25% | Hisse senetleri |
| Amundi | $93.528.650 | 412.402 | 1,19% | Hisse senetleri |
| NORGES BANK | $83.921.372 | 370.040 | 1,07% | Hisse senetleri |
| MARSHALL WACE, LLP | $76.947.125 | 339.288 | 0,98% | Hisse senetleri |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,97% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,83% | Hisse senetleri |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,82% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,81% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $63.095.473 | 278.211 | 0,81% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,78% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,77% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $57.319.812 | 252.744 | 0,73% | Hisse senetleri |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,72% | Hisse senetleri |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,68% | Hisse senetleri |
| Quantinno Capital Management LP | $49.020.824 | 216.150 | 0,63% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48.415.129 | 213.480 | 0,62% | Hisse senetleri |
| Boston Trust Walden Corp | $46.506.918 | 205.066 | 0,59% | Hisse senetleri |
| Burgundy Asset Management Ltd. | $45.453.909 | 278.329 | 0,58% | Hisse senetleri |
| SRS Investment Management, LLC | $42.496.817 | 187.384 | 0,54% | Hisse senetleri |
| LOOMIS SAYLES & CO L P | $38.517.487 | 169.838 | 0,49% | Hisse senetleri |
| JONES FINANCIAL COMPANIES LLLP | $37.184.513 | 172.350 | 0,47% | Hisse senetleri |
| PERCEPTIVE ADVISORS LLC | $31.750.600 | 140.000 | 0,41% | Hisse senetleri |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30.389.860 | 134.000 | 0,39% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $29.879.583 | 131.750 | 0,38% | Hisse senetleri |
| BlackRock, Inc. | $29.025.945 | 127.986 | 0,37% | Hisse senetleri |
| PICTON MAHONEY ASSET MANAGEMENT | $26.340.305 | 116.144 | 0,34% | Hisse senetleri |
| FIL Ltd | $25.184.576 | 111.048 | 0,32% | Hisse senetleri |
| Candriam S.C.A. | $23.824.478 | 105.152 | 0,30% | Hisse senetleri |
| Clark Capital Management Group, Inc. | $23.010.567 | 101.462 | 0,29% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $22.453.344 | 99.005 | 0,29% | Hisse senetleri |
| Swiss National Bank | $22.452.210 | 99.000 | 0,29% | Hisse senetleri |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20.491.384 | 90.354 | 0,26% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $20.280.546 | 89.424 | 0,26% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.730.730 | 87.000 | 0,25% | Alım opsiyonu |
| NOMURA HOLDINGS INC | $19.672.672 | 86.744 | 0,25% | Hisse senetleri |
| RHUMBLINE ADVISERS | $19.484.825 | 85.916 | 0,25% | Hisse senetleri |
| Ilex Capital Partners (UK) LLP | $18.413.760 | 81.193 | 0,24% | Hisse senetleri |
| Aristotle Capital Boston, LLC | $18.273.438 | 80.574 | 0,23% | Hisse senetleri |
| CITADEL ADVISORS LLC | $17.485.509 | 77.100 | 0,22% | Alım opsiyonu |
| NICHOLAS COMPANY, INC. | $16.305.067 | 71.895 | 0,21% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15.172.024 | 66.899 | 0,19% | Hisse senetleri |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15.164.087 | 66.864 | 0,19% | Hisse senetleri |
| Ranger Investment Management, L.P. | $15.009.416 | 66.182 | 0,19% | Hisse senetleri |
| California Public Employees Retirement System | $14.670.818 | 64.689 | 0,19% | Hisse senetleri |
| Assenagon Asset Management S.A. | $14.020.385 | 61.821 | 0,18% | Hisse senetleri |
| ASSETMARK, INC | $13.939.194 | 61.463 | 0,18% | Hisse senetleri |
| Rhenman & Partners Asset Management AB | $12.972.388 | 57.200 | 0,17% | Hisse senetleri |
| RIVERBRIDGE PARTNERS LLC | $12.859.587 | 56.703 | 0,16% | Hisse senetleri |
| TD Asset Management Inc | $12.854.230 | 56.679 | 0,16% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12.836.314 | 56.600 | 0,16% | Satım opsiyonu |
| Laurus Investment Counsel Inc. | $12.365.663 | 71.685 | 0,16% | Hisse senetleri |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12.204.023 | 53.812 | 0,16% | Hisse senetleri |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11.552.133 | 50.938 | 0,15% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10.732.081 | 47.278 | 0,14% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $10.506.727 | 46.328 | 0,13% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $10.472.482 | 46.177 | 0,13% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $9.914.950 | 43.719 | 0,13% | Hisse senetleri |
| BARCLAYS PLC | $9.909.816 | 43.696 | 0,13% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9.827.670 | 56.972 | 0,13% | Hisse senetleri |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9.382.529 | 41.371 | 0,12% | Hisse senetleri |
| Park West Asset Management LLC | $9.343.748 | 41.200 | 0,12% | Hisse senetleri |
| State of Tennessee, Department of Treasury | $8.457.000 | 37.290 | 0,11% | Hisse senetleri |
| J.P. Marvel Investment Advisors, LLC | $8.456.092 | 37.286 | 0,11% | Hisse senetleri |
| CASTLEARK MANAGEMENT LLC | $8.174.646 | 36.045 | 0,10% | Hisse senetleri |
| JANE STREET GROUP, LLC | $7.869.613 | 34.700 | 0,10% | Alım opsiyonu |
| Pine Ridge Advisers LLC | $7.710.860 | 34.000 | 0,10% | Hisse senetleri |
| PRUDENTIAL FINANCIAL INC | $7.346.635 | 32.394 | 0,09% | Hisse senetleri |
| Capricorn Fund Managers Ltd | $7.092.630 | 31.274 | 0,09% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $7.000.554 | 30.868 | 0,09% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $6.951.290 | 30.651 | 0,09% | Hisse senetleri |
| Caption Management, LLC | $6.803.700 | 30.000 | 0,09% | Satım opsiyonu |
| Engineers Gate Manager LP | $6.637.463 | 29.267 | 0,08% | Hisse senetleri |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6.351.027 | 28.004 | 0,08% | Hisse senetleri |
| Midwest Trust Co | $6.091.126 | 26.858 | 0,08% | Hisse senetleri |
| VAN ECK ASSOCIATES CORP | $5.942.578 | 26.203 | 0,08% | Hisse senetleri |
| SEI INVESTMENTS CO | $5.929.630 | 26.150 | 0,08% | Hisse senetleri |
| Sendero Wealth Management, LLC | $5.909.468 | 26.057 | 0,08% | Hisse senetleri |
| 13D Management LLC | $5.851.182 | 25.800 | 0,07% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5.500.853 | 31.889 | 0,07% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $5.462.691 | 24.087 | 0,07% | Hisse senetleri |
| INVESTMENT HOUSE LLC | $5.447.042 | 24.018 | 0,07% | Hisse senetleri |
| LPL Financial LLC | $5.409.169 | 23.851 | 0,07% | Hisse senetleri |
| LRT Capital Management, LLC | $5.348.842 | 23.585 | 0,07% | Hisse senetleri |
Şirket yöneticileri 57 içeriden öğrenenler · 21 yöneticiler · 27 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 29 Mayıs 2026 A | 27.752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | 31 Mayıs 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 03 Mart 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 Temmuz 2018 M | 17.155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | 31 Mayıs 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 07 Kasım 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 01 Haziran 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 Mayıs 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 01 Ekim 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 02 Mart 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 Şubat 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 Ağustos 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 Şubat 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 Ağustos 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 Haziran 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 01 Mayıs 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 02 Nisan 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 02 Nisan 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 Şubat 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 Şubat 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 Aralık 2004 M | 8.000 | 0 | 0 | $0 |
| Steven Barg | Yönetim kurulu üyesi | 02 Haziran 2026 A | 3.287 | 0 | 0 | $0 |
| Nancy C Andrews | Yönetim kurulu üyesi | 12 Mayıs 2026 G | 3.964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Yönetim kurulu üyesi | 08 Mayıs 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Yönetim kurulu üyesi | 15 Mayıs 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Yönetim kurulu üyesi | 07 Kasım 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Yönetim kurulu üyesi | 13 Mayıs 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Yönetim kurulu üyesi | 13 Mayıs 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Yönetim kurulu üyesi | 15 Mayıs 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Yönetim kurulu üyesi | 07 Mayıs 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Yönetim kurulu üyesi | 23 Şubat 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Yönetim kurulu üyesi | 22 Mayıs 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Yönetim kurulu üyesi | 05 Aralık 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Yönetim kurulu üyesi | 09 Mayıs 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Yönetim kurulu üyesi | 07 Mayıs 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Yönetim kurulu üyesi | 07 Mayıs 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Yönetim kurulu üyesi | 13 Şubat 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Yönetim kurulu üyesi | 25 Şubat 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Yönetim kurulu üyesi | 17 Şubat 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Yönetim kurulu üyesi | 17 Şubat 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Yönetim kurulu üyesi | 02 Haziran 2004 G | 278.600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | 11 Ağustos 2026 M | 4.807 | 0 | 2 | $-2.365.755 |
| Birgit Girshick | — | 11 Ağustos 2026 M | 36.013 | 0 | 1 | $-1.819.350 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 başvurular | 04 Ağustos 2011 | — | İlk başvuru | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 başvurular | 09 Şubat 2011 | — | İlk başvuru | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 başvurular | 07 Aralık 2010 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 16 Haziran 2010 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 07 Haziran 2010 | — | İlk başvuru | Pasif yatırım | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 05 Mayıs 2010 | — | İlk başvuru | Yönetim kurulu kampanyası | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 135 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2,18% | 63.652 SH | 08 Ağustos 2026 | Günlük |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,49% | 4.749 NS | 30 Nisan 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1,33% | 370 NS | 30 Nisan 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1,18% | 41.597 SH | 08 Ağustos 2026 | Günlük |
| EPMV · Harbor ETF Trust | 1,09% | 291 NS | 30 Nisan 2026 | N-PORT |
| IBB · iShares Trust | 0,97% | 349.491 SH | 08 Ağustos 2026 | Günlük |
| EPSV · Harbor ETF Trust | 0,90% | 270 NS | 30 Nisan 2026 | N-PORT |
| TAX · EA Series Trust | 0,80% | 1.131 NS | 29 Mayıs 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,66% | 612 NS | 30 Nisan 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,50% | 2.356 NS | 30 Nisan 2026 | N-PORT |
| ISCV · iShares Trust | 0,40% | 10.497 SH | 08 Ağustos 2026 | Günlük |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,38% | 11.925 NS | 30 Nisan 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,38% | 25.401 SH | 08 Ağustos 2026 | Günlük |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | 0,36% | 1.145.000 PA | 08 Ağustos 2026 | Günlük |
| IQSM · New York Life Investments ETF Trust | 0,33% | 6.161 NS | 30 Nisan 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,29% | 22.440 NS | 30 Nisan 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,27% | 996.151 SH | 08 Ağustos 2026 | Günlük |
| DFAT · Dimensional ETF Trust | 0,26% | 212.321 NS | 30 Nisan 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 08 Ağustos 2026 | Günlük |
| ESML · iShares Trust | 0,23% | 24.979 SH | 08 Ağustos 2026 | Günlük |
| BKMC · BNY Mellon ETF Trust | 0,22% | 8.115 NS | 30 Nisan 2026 | N-PORT |
| IYH · iShares Trust | 0,21% | 29.370 SH | 08 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | 0,20% | 2.125 SH | 08 Ağustos 2026 | Günlük |
| SMMD · iShares Trust | 0,17% | 24.455 SH | 08 Ağustos 2026 | Günlük |
| FSMD · FIDELITY COVINGTON TRUST | 0,17% | 24.528 NS | 30 Nisan 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,17% | 133.341 NS | 31 Mayıs 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,16% | 138.243 NS | 30 Nisan 2026 | N-PORT |
| IXJ · iShares Trust | 0,16% | 25.598 SH | 08 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 08 Ağustos 2026 | Günlük |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 18.369 NS | 30 Nisan 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,15% | 6.079 NS | 31 Mayıs 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 6.018 SH | 08 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,13% | 22.674 NS | 30 Nisan 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,13% | 59.338 NS | 30 Nisan 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 08 Ağustos 2026 | Günlük |
| VGMS · VANGUARD MALVERN FUNDS | 0,13% | 315.000 PA | 08 Ağustos 2026 | Günlük |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,13% | 4.072 SH | 08 Ağustos 2026 | Günlük |
| RXL · ProShares Trust | 0,13% | 513 NS | 31 Mayıs 2026 | N-PORT |
| IWS · iShares Trust | 0,13% | 74.284 SH | 08 Ağustos 2026 | Günlük |
| REVS · Columbia ETF Trust I | 0,12% | 2.082 NS | 30 Nisan 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,12% | 982 NS | 30 Nisan 2026 | N-PORT |
| SMLF · iShares Trust | 0,12% | 18.532 SH | 08 Ağustos 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 3.280 NS | 30 Nisan 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,11% | 1.032 NS | 30 Nisan 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 199.595 SH | 08 Ağustos 2026 | Günlük |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,09% | 1.986 NS | 31 Mayıs 2026 | N-PORT |
| IEUS · iShares Trust | 0,09% | 4.951 SH | 08 Ağustos 2026 | Günlük |
| XOEF · iShares Trust | 0,07% | 61 SH | 08 Ağustos 2026 | Günlük |
| VSDB · VANGUARD MALVERN FUNDS | 0,07% | 635.000 PA | 08 Ağustos 2026 | Günlük |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 5.261 NS | 30 Nisan 2026 | N-PORT |